CompletedPhase 2

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

Germany48 participantsStarted 2006-12

Plain-language summary

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: \- Stable or exacerbating seborrheic dermatitis in the facial area Exclusion Criteria: * Psoriasis * Atopic dermatitis * Facial acne and rosacea * Dermatophytic skin infections * Parkinson's disease * Known immunosuppression; HIV infection * Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy * Continuous asthma inhalation treatment requiring \> 800 mg corticosteroids * Any severe disease likely to interfere with the conduct or the planned termination of the study

What they're measuring

Sum Score of the symptoms of seborrheic dermatitis and the investigator's global assessment.

Timeframe: Measurement of parameters during the course of treatment (six weeks)

Trial details

NCT IDNCT00408330

SponsorLEO Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2007-03

View on ClinicalTrials.gov More Seborrheic Dermatitis on the Face trials